SCHEMBL8098254

SCHEMBL8098254

FC(F)(F)c1ccc(C(OCCN2CCN(c3ccc(Cc4ccccc4)cc3)CC2)c2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 9/20 0.62
SLC6A3 Q01959 8/20 0.62
SLC6A2 P23975 6/20 0.62
HTR1A P08908 3/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
CYP2C9 P11712 3/20 0.53
MAPK1 P28482 3/20 0.53
SIGMAR1 Q99720 3/20 0.53
TP53 P04637 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2D6 P10635 2/20 0.53
MAPT P10636 2/20 0.53
TSHR P16473 2/20 0.53
NFKB1 P19838 2/20 0.53
CYP2C19 P33261 2/20 0.53
THPO P40225 2/20 0.53
MTOR P42345 2/20 0.53
RAB9A P51151 2/20 0.53
HIF1A Q16665 2/20 0.53
ALOX15 P16050 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4667575 0.80 CYP2D6 (0.58) SLC6A4SLC6A3SLC6A2HTR1ACYP2C9
SCHEMBL4667595 0.75 FFAR1 (0.52) SLC6A4SLC6A3SLC6A2SMN1; SMN2CYP2C9
SCHEMBL10357800 0.74 SIGMAR1 (0.81) SLC6A4SLC6A3SLC6A2HTR1ASMN1; SMN2
SCHEMBL10554467 0.72 SLC6A4 (0.62) SLC6A4SLC6A3SLC6A2SMN1; SMN2CYP2C9
SCHEMBL30671730 0.72 SIGMAR1 (0.73) SLC6A4SLC6A2HTR1ASIGMAR1KCNH2
SCHEMBL15442411 0.72 HRH3 (0.62) SLC6A4SLC6A2HTR1ASIGMAR1MAPT
Hydrochloric Acid SCHEMBL10573209 0.71 SIGMAR1 (0.59) SLC6A4SLC6A3SLC6A2SMN1; SMN2MAPK1
SCHEMBL350747 0.70 HTR1A (0.88) SLC6A4SLC6A3SLC6A2HTR1AKCNH2
SCHEMBL1506074 0.70 SLC6A3 (0.79) SLC6A3
SCHEMBL2115675 0.70 ADRB1 (0.72) HTR1ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0983222-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 2000-03-08 EP disclosed
WO-1998052898-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 1998-11-26 WO disclosed